HIV-specific antibody-dependent cellular cytotoxicity: A novel vaccine modality

Expert Review of Clinical Immunology

Volumn 8, Issue 8, 2012, Pages 767-774

  Madhavi, Vijaya ^a   Kent, Stephen J ^a   Stratov, Ivan ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ADCC; antibodies; HIV; NK cells; vaccine

Indexed keywords

CD56 ANTIGEN; ERDOSTEINE; FC RECEPTOR; GLYCOPROTEIN GP 120; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; NEF PROTEIN; PLACEBO; POL PROTEIN; RECOMBINANT GLYCOPROTEIN GP 120; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS 5; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CYTOMETRY; DISEASE CONTROL; DISEASE COURSE; EFFECTOR CELL; FLUORESCENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LYMPHOBLASTOID CELL; MACACA; MUTAGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN GLYCOSYLATION; REVIEW; SIMIAN; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIREMIA; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY;

EID: 84869830733     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.74     Document Type: Review

References (75)

1. Assembly UG. UN General Assembly High Level Meeting on AIDS. New York, NY, USA, 8-10 June 2011.).
2. Pitisuttithum P. HIV-1 prophylactic vaccine trials in Thailand. Curr. HIV Res. 3(1), 17-30 (2005). (Pubitemid 40081282)
3. Allers K, Hutter G, Hofmann J et al. Evidence for the cure of HIV infection by CCR5Δ32/32 stem cell transplantation. Blood 117(10), 2791-2799 (2011).
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510), 123-126 (1995).
5. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100(7), 4144-4149 (2003). (Pubitemid 36418171)
6. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 422(6929), 307-312 (2003). (Pubitemid 36378357)
7. Connor RI, Korber BT, Graham BS et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72(2), 1552-1576 (1998). (Pubitemid 28116944)
8. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5(2), 204-210 (1999). (Pubitemid 29068528)
9. Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA primemodified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73(9), 7524-7532 (1999). (Pubitemid 29383236)
10. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLArestricted immune responses at a population level. Science 296(5572), 1439-1443 (2002). (Pubitemid 34553083)
11. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391(6665), 397-401 (1998). (Pubitemid 28093515)
12. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258(5090), 1938-1941 (1992). (Pubitemid 23026733)
13. Baba TW, Liska V, Khimani AH et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5(2), 194-203 (1999). (Pubitemid 29068527)
14. Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270(5238), 988-991 (1995).
15. Kent SJ, Dale CJ, Preiss S, Purcell DF. Evidence of recombination between 3' and 5/ LTRs in macaques inoculated with SIV DNA. AIDS Res. Hum. Retroviruses 18(3), 227-230 (2002). (Pubitemid 34161243)
16. Robinson HL, Montefiori DC, Johnson RP et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5(5), 526-534 (1999). (Pubitemid 29220211)
17. Learmont JC, Geczy AF, Mills J et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340(22), 1715-1722 (1999). (Pubitemid 29252599)
18. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
19. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebocontrolled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654-665 (2005).
20. Buchbinder SP, Mehrotra DV, Duerr A et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
21. Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 303(5656), 316 (2004). (Pubitemid 38095757)
22. Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1(1), 59-64 (1995).
23. Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102(9), 1758-1765 (1998). (Pubitemid 28516261)
24. Kaul R, Rowland-Jones SL, Kimani J et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J. Clin. Invest. 107(3), 341-349 (2001). (Pubitemid 32157966)
25. Scott-Algara D, Truong LX, Versmisse P et al. Cutting edge: Increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171(11), 5663-5667 (2003). (Pubitemid 37467178)
26. Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science 295(5560), 1616-1617 (2002). (Pubitemid 34202866)
27. Russell ND, Graham BS, Keefer MC et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: Negative results fail to trigger a Phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44(2), 203-212 (2007). (Pubitemid 46292224)
28. Nitayaphan S, Pitisuttithum P, Karnasuta C et al.; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190(4), 702-706 (2004). (Pubitemid 39049999)
29. Karnasuta C, Paris RM, Cox JH et al.; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a Phase I/II ALVAC-HIV/AIDSVAX B/E primeYboost HIV-1 vaccine trial in Thailand. Vaccine 23(19), 2522-2529 (2005). (Pubitemid 40332524)
30. Hope TJ. Moving ahead an HIV vaccine: To neutralize or not, a key HIV vaccine question. Nat. Med. 17(10), 1195-1197 (2011).
31. Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158), 101-104 (2007). (Pubitemid 47373775)
32. Chung AW, Navis M, Isitman G et al. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 24(2), 171-175 (2011).
33. Chung AW, Navis M, Isitman G et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 58(2), 127-131 (2011).
34. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275-1286 (2012).
35. Baum LL, Cassutt KJ, Knigge K et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157(5), 2168-2173 (1996). (Pubitemid 126449697)
36. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75(15), 6953-6961 (2001). (Pubitemid 32641582)
37. Benson J, Chougnet C, Robert-Guroff M et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure. J. Virol. 72(5), 4170-4182 (1998). (Pubitemid 28188722)
38. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2(8) (2012).
39. Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 114(5), 605-610 (2004). (Pubitemid 39578747)
40. Chen P, Hubner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Envdependent neutralization-resistant virological synapses. J. Virol. 81(22), 12582-12595 (2007). (Pubitemid 350085872)
41. Hubner W, McNerney GP, Chen P et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 323(5922), 1743-1747 (2009).
42. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84(7), 3516-3527 (2010).
43. Massanella M, Puigdomenech I, Cabrera C et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 23(2), 183-188 (2009).
44. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182(2), 1202-1210 (2009).
45. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J. Virol. 82(11), 5450-5459 (2008). (Pubitemid 351705252)
46. Alter G, Altfeld M. NK cell function in HIV-1 infection. Curr. Mol. Med. 6(6), 621-629 (2006). (Pubitemid 44377761)
47. Alter G, Heckerman D, Schneidewind A et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476(7358), 96-100 (2011).
48. Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: Neutralisation and antibody effector functions. Trends Microbiol. 16(12), 596-604 (2008).
49. Naz RK. Female genital tract immunity: Distinct immunological challenges for vaccine development. J. Reprod. Immunol. 93(1), 1-8 (2012).
50. Shacklett BL. Cell-mediated immunity to HIV in the female reproductive tract. J. Reprod. Immunol. 83(1-2), 190-195 (2009).
51. Yamada T, Watanabe N, Nakamura T, Iwamoto A. Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J. Immunol. 172(4), 2401-2406 (2004). (Pubitemid 38182389)
52. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412(1), 110-116 (2011).
53. Chung AW, Isitman G, Navis M et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc. Natl Acad. Sci. USA 108(18), 7505-7510 (2011).
54. Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23(8), 897-906 (2009).
55. Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS 24(11), 1633-1640 (2010).
56. Moldt B, Shibata-Koyama M, Rakasz EG et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86(11), 6189-6196 (2012).
57. Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, Baum LL. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J. Infect. Dis. 185(4), 439-447 (2002). (Pubitemid 34142805)
58. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog. 8(6), e1002739 (2012).
59. Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01-AE gp120. AIDS Res. Hum. Retroviruses 28(10), 1250-1258 (2012).
60. Ferrari G, Pollara J, Kozink D et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 85(14), 7029-7036 (2011).
61. Wren L, Chung A, Kent SJ et al. specific antibody dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology(2012) (In Press).
62. Holl V, Peressin M, Moog C. Antibodymediated Fcγ receptor-based mechanisms of HIV inhibition: Recent findings and new vaccination strategies. Viruses 1(3), 1265-1294 (2009).
63. Liu Q, Sun Y, Rihn S et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J. Virol. 83(17), 8705-8712 (2009).
64. Moldt B, Schultz N, Dunlop DC et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. J. Virol. 85(20), 10572-10581 (2011).
65. Forthal DN, Landucci G, Katz J, Tilles JG. Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J. Infect. Dis. 168(4), 1020-1023 (1993). (Pubitemid 23282581)
66. Sung MW, Nagashima S, Johnson JT, Van Dongen GA, Whiteside TL. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets. Cell. Immunol. 171(1), 20-29 (1996). (Pubitemid 26349120)
67. Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 19(3), 184-191 (1996). (Pubitemid 26234612)
68. Forthal DN, Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J. Immunol. Methods 220(1-2), 129-138 (1998). (Pubitemid 28527075)
69. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80(18), 9217-9225 (2006). (Pubitemid 44359994)
70. Gomez-Roman VR, Florese RH, Patterson LJ et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308(1-2), 53-67 (2006). (Pubitemid 43107954)
71. Kantakamalakul W, Pattanapanyasat K, Jongrakthaitae S, Assawadarachai V, Ampol S, Sutthent R. A novel EGFPCEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J. Immunol. Methods 315(1-2), 1-10 (2006). (Pubitemid 44414817)
72. Pollara J, Hart L, Brewer F et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry. A 79(8), 603-612 (2011).
73. Eller MA, Eller LA, Opollo MS et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 25(45), 7737-7742 (2007). (Pubitemid 47588523)
74. Gomez-Roman VR, Patterson LJ, Venzon D et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174(4), 2185-2189 (2005). (Pubitemid 40223963)
75. Xiao P, Zhao J, Patterson LJ et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 84(14), 7161-7173 (2010